echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The treatment of Alzheimer's disease and Parkinson's disease is expected to gain Pfizer's new treatment by US $700 million

    The treatment of Alzheimer's disease and Parkinson's disease is expected to gain Pfizer's new treatment by US $700 million

    • Last Update: 2020-01-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 14, Biogen announced that it had reached an agreement with Pfizer to harvest Pfizer's clinical in-process treatment pf-0251749 This is a small molecule inhibitor of casein kinase 1 (CK1), which can cross the blood-brain barrier and enter the central nervous system It can be used to treat behavior and neurological symptoms caused by a variety of mental or neurological diseases Bojian plans to develop this innovative therapy in phase 1 clinical development stage to treat sundown syndrome in patients with Alzheimer's disease (AD) and irregular sleep wake rhythm disorder (iswrd) in patients with Parkinson's disease (PD) CK1 is an important regulator of the suprachiasmatic nucleus in the hypothalamus It regulates circadian rhythms and has an important influence on almost all key physiology and metabolism Circadian dysrhythmia is associated with a variety of mental and neurological disorders, including important symptoms in patients with AD and PD Sunset syndrome affects more than 20% of AD patients They get confused, upset, excited and aggressive later in the day Iswrd is a kind of circadian rhythm disorder, which leads to sleep fragmentation at night, sleepiness during the day, severe fatigue, and difficulty in completing daily activities This is one of the non motor symptoms of PD patients, with the development of the disease frequency increased Photo source: 123rf Pf-05251749 has demonstrated an acceptable concept of safety and mechanism of action in phase 1 clinical trials Bojian plans to launch phase 1b clinical research in the fourth quarter of this year To explore the effect of it on improving the symptoms of sunset syndrome and iswrd in AD patients by correcting circadian rhythm Under the agreement, Bojian will pay Pfizer $75 million in upfront payments, up to $635 million in milestone payments, and a share of future sales "This in-process therapy is highly complementary to our ad and PD drug development pipeline that potentially changes the disease process," said Dr Alfred sandrock Jr., chief medical officer and executive vice president of research and development of Bojian "Many ad and PD patients suffer from severe sleep disorders and restlessness, and we believe that the regulation of circadian rhythm may have the hope to solve these behaviors and neurological symptoms " reference material: [1] Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc Retrieved January 13, 2020, from https:// Note: the purpose of this article is to introduce the progress of medical health research, not to recommend the treatment plan For guidance on treatment options, please visit a regular hospital Original title: express delivery for Alzheimer's disease and Parkinson's disease patients, Bojian reaps 700 million US dollars of innovative circadian rhythm therapy A kind of
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.